Brown Capital Management released its Q4 2025 investor letter for “The Brown Capital Management Small Company Fund”, reporting a 1.50% loss behind the Russell 2000® Growth index. Real estate and telecommunications led the benchmark’s performance. Veracyte, Inc. stock closed at $35.63 per share with a one-month return of -12.18% and a market cap of $2.817 billion.

The Fund added Veracyte, Inc. and three other companies in Q4 2025. Veracyte is a genomic diagnostics company with dominant market share in key products like Decipher and Afirma. The company turned profitable in 2024 and has shown margin expansion. Veracyte’s pipeline could expand its market opportunity by over $3 billion.

Veracyte, Inc. was held by 27 hedge fund portfolios at the end of Q4 2025. While the company shows potential, certain AI stocks may offer greater upside. Another article covered Veracyte and listed it among the best innovative stocks to buy. Check hedge fund investor letters for more insights and analysis.

Read more at Yahoo Finance: Does Veracyte (VCYT) Offer Both Strength and Opportunity?